ERBB2 and breast carcinoma: After its initial role in HER-2-positive breast cancer, trastuzumab proved to also increase overall survival in metastatic gastric cancer when associated with first-line chemotherapy [51], which is now the standard initial treatment for HER-2-positive advanced gastric cancer, in combination with pembrolizumab [14].